High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy

Y Kusano; M Yokoyama; Y Terui; N Inoue; A Takahashi; H Yamauchi; N Tsuyama; N Nishimura; Y Mishima; K Takeuchi; K Hatake

首页> 外文期刊>Blood cancer journal. >High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy

【24h】

High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy

机译：可溶性白细胞介素2受体的高预处理水平是使用R-CHOP样疗法治疗的滤泡性淋巴瘤患者的强有力的预后因素

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Follicular lymphoma (FL) is one of the most common subtypes of non-Hodgkin lymphoma. Indolent lymphomas including FL are generally considered as incurable, which impacts the treatment goals including progression-free survival (PFS) and time to next treatment (TTNT).

机译：滤泡性淋巴瘤（FL）是非霍奇金淋巴瘤最常见的亚型之一。包括FL在内的惰性淋巴瘤通常被认为是不可治愈的，这会影响包括无进展生存期（PFS）和下次治疗时间（TTNT）在内的治疗目标。

著录项

来源
《Blood cancer journal.》 |2017年第9期|共页
作者
Y Kusano; M Yokoyama; Y Terui; N Inoue; A Takahashi; H Yamauchi; N Tsuyama; N Nishimura; Y Mishima; K Takeuchi; K Hatake;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类医学免疫学;
关键词

相似文献

外文文献
中文文献
专利

1. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era [J] . ProcházkaV., PapajíkT., FaberE., Leukemia and lymphoma . 2014,第7期

机译：可溶性白细胞介素2受体水平预测利妥昔单抗时代用环磷酰胺，阿霉素，长春新碱和泼尼松化疗治疗的滤泡性淋巴瘤患者的生存
2. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. [J] . Oki Y, Kato H, Matsuo K, Leukemia and lymphoma . 2008,第7期

机译：血清可溶性白介素2受体水平在弥散性大B细胞淋巴瘤患者中的预后价值，采用基于CHOP或RCHOP的治疗。
3. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP [J] . Kento Umino, Shin-ichiro Fujiwara, Takashi Ikeda, Hematology . 2017,第9期

机译：滤泡性淋巴瘤患者达到R-CHOP反应后可溶性白介素2受体水平的预后价值
4. PET WITH ~(18)FDG AND SPECT WITH ~(99)Tc~m-SESTAMIBI FOR THERAPY MANAGEMENT IN PATIENTS WITH TREATED MALIGNANT LYMPHOMAS [C] . L.G. STRAUSS, A. DIMITRAKOPOULOU-STRAUSS, H. GOLDSCHMIDT, Tomography in nuclear medicine . 1995

机译：含〜（18）FDG的PET和含〜（99）Tc〜m-SESTAMIBI的SPECT用于治疗恶性淋巴瘤的患者的治疗
5. Prognostic Biomarkers for Diffuse Large B Cell Lymphoma Patient Survival after Treatment with Chemotherapy: A Retrospective Analysis of 88 Cases [D] . Bushra, Hamama tul. 2019

机译：弥漫性大B细胞淋巴瘤化疗后患者生存的预后生物标志物：88例回顾性分析
6. High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy [O] . Y Kusano, M Yokoyama, Y Terui, 2017

机译：可溶性白细胞介素2受体的高预处理水平是接受R-CHOP样疗法治疗的滤泡性淋巴瘤患者的有力预后因素
7. High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy [O] . Y Kusano, M Yokoyama, Y Terui, 2017

机译：可溶性白细胞介素-2受体的高预处理水平是用R-Chootph样疗法治疗的滤泡淋巴瘤患者的稳健预后因子

High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy

摘要

著录项

相似文献

相关主题

期刊订阅